Trial
NCT02427581
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Susan G. Komen Breast Cancer Foundation
Condition
Triple Negative Breast Cancer
Intervention
Personalized synthetic long peptide vaccine (Poly ICLC)
Why stopped
Drugs not available
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-10